PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29934640-0 2018 Distinct submembrane localisation compartmentalises cardiac NPR1 and NPR2 signalling to cGMP. Cyclic GMP 88-92 natriuretic peptide receptor 1 Homo sapiens 60-64 33375031-3 2020 Natriuretic Peptides (NPs), Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP), binding to Natriuretic Peptide Receptor-1 (NPR-1), signal by increasing cGMP (cyclic guanosine monophosphate) levels that, in turn, stimulate cGMP-dependent protein kinase-I (PKG-I). Cyclic GMP 171-175 natriuretic peptide receptor 1 Homo sapiens 110-140 33375031-3 2020 Natriuretic Peptides (NPs), Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP), binding to Natriuretic Peptide Receptor-1 (NPR-1), signal by increasing cGMP (cyclic guanosine monophosphate) levels that, in turn, stimulate cGMP-dependent protein kinase-I (PKG-I). Cyclic GMP 171-175 natriuretic peptide receptor 1 Homo sapiens 142-147 33375031-3 2020 Natriuretic Peptides (NPs), Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP), binding to Natriuretic Peptide Receptor-1 (NPR-1), signal by increasing cGMP (cyclic guanosine monophosphate) levels that, in turn, stimulate cGMP-dependent protein kinase-I (PKG-I). Cyclic GMP 177-207 natriuretic peptide receptor 1 Homo sapiens 110-140 33375031-3 2020 Natriuretic Peptides (NPs), Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP), binding to Natriuretic Peptide Receptor-1 (NPR-1), signal by increasing cGMP (cyclic guanosine monophosphate) levels that, in turn, stimulate cGMP-dependent protein kinase-I (PKG-I). Cyclic GMP 177-207 natriuretic peptide receptor 1 Homo sapiens 142-147 30951863-4 2019 We review emerging concepts of receptor endocytosis with concurrent intracellular signaling, using a typical example of guanylyl cyclase/natriuretic peptide receptor-A (NPRA) internalization, subcellular trafficking, and simultaneous generation of second-messenger cGMP and signaling in intact cells. Cyclic GMP 265-269 natriuretic peptide receptor 1 Homo sapiens 169-173 31430210-2 2019 NPR-A catalyzes the intracellular conversion of guanosine triphosphate to cGMP (cyclic 3",5"-guanosine monophosphate) on binding of ANP, BNP (atrial or brain natriuretic peptide). Cyclic GMP 74-78 natriuretic peptide receptor 1 Homo sapiens 0-5 31430210-2 2019 NPR-A catalyzes the intracellular conversion of guanosine triphosphate to cGMP (cyclic 3",5"-guanosine monophosphate) on binding of ANP, BNP (atrial or brain natriuretic peptide). Cyclic GMP 80-116 natriuretic peptide receptor 1 Homo sapiens 0-5 31430210-8 2019 Cells transiently expressing 967K or 1034F NPR-A displayed decreased cGMP production in response to ANP and BNP (all P<10-6), while cells expressing 541S NPR-A produced more cGMP compared with cells expressing wild-type NPR-A (P<=4.13x10-5 for ANP and P<=4.24x10-3 for BNP). Cyclic GMP 69-73 natriuretic peptide receptor 1 Homo sapiens 43-48 31817347-11 2019 After the NPR1 knockdown of HEK-293 cells, cGMP activity was not changed. Cyclic GMP 43-47 natriuretic peptide receptor 1 Homo sapiens 10-14 31439665-5 2019 Mechanistically, E2 enhanced the interaction of membrane ERalpha with the Galpha subunit Galphai-2/3, which then transactivated particulate guanylate cyclase-A (pGC-A) to produce cGMP, thereby activating protein kinase G type I (PKG-I). Cyclic GMP 179-183 natriuretic peptide receptor 1 Homo sapiens 140-159 29934640-2 2018 In the heart, two natriuretic peptide receptors NPR1 and NPR2 act as membrane guanylyl cyclases to produce 3",5"-cyclic guanosine monophosphate (cGMP). Cyclic GMP 145-149 natriuretic peptide receptor 1 Homo sapiens 48-52 28626572-3 2017 The endogeneous hormone ANP signals via the natriuretic peptide receptor A (NPR-A) through raising intracellular cGMP concentrations, and is involved in blood pressure regulation and sodium homeostasis, as well as lipid metabolism and pancreatic function. Cyclic GMP 113-117 natriuretic peptide receptor 1 Homo sapiens 44-74 28626572-3 2017 The endogeneous hormone ANP signals via the natriuretic peptide receptor A (NPR-A) through raising intracellular cGMP concentrations, and is involved in blood pressure regulation and sodium homeostasis, as well as lipid metabolism and pancreatic function. Cyclic GMP 113-117 natriuretic peptide receptor 1 Homo sapiens 76-81 28626572-4 2017 The cis- and trans-isomers of one of our peptidomimetics, termed TOP271, exhibit a four-fold difference in NPR-A mediated cGMP synthesis in vitro. Cyclic GMP 122-126 natriuretic peptide receptor 1 Homo sapiens 107-112 28096344-7 2017 The atrial natriuretic peptide secreted by atrial myocytes is a major adipogenic factor operating at a low concentration by binding to its natriuretic peptide receptor A (NPRA) receptor and, in turn, by activating a cGMP-dependent pathway. Cyclic GMP 216-220 natriuretic peptide receptor 1 Homo sapiens 139-169 28096344-7 2017 The atrial natriuretic peptide secreted by atrial myocytes is a major adipogenic factor operating at a low concentration by binding to its natriuretic peptide receptor A (NPRA) receptor and, in turn, by activating a cGMP-dependent pathway. Cyclic GMP 216-220 natriuretic peptide receptor 1 Homo sapiens 171-175 26701223-4 2016 NPR-A (which binds ANP, BNP and DNP) and NPR-B (which is selective for CNP) are particulate guanylyl cyclase (GC)-linked receptors that mediate increases in cGMP upon activation. Cyclic GMP 157-161 natriuretic peptide receptor 1 Homo sapiens 0-5 27786597-2 2016 They signal through the NPRA/cGMP system and are inactivated by a clearance receptor NPRC and neutral endopeptidases (NEP). Cyclic GMP 29-33 natriuretic peptide receptor 1 Homo sapiens 24-28 26616294-10 2016 We provided new evidence of the direct involvement of ANP/NPR-1/cGMP axis on NF-kB/NALP3/caspase-1-mediated IL-1beta release and NF-kB-mediated pro-IL-1beta production. Cyclic GMP 64-68 natriuretic peptide receptor 1 Homo sapiens 58-63 25202235-4 2014 The activation of NPRA and NPRB produces the intracellular second messenger cGMP, which serves as the major signaling molecule of all three NPs. Cyclic GMP 76-80 natriuretic peptide receptor 1 Homo sapiens 18-22 25843350-4 2015 In cell lines expressing endogenous natriuretic peptide receptor A (NPR-A) (HeLa), GTA/PGTA-driven transgene expression was induced by B-type natriuretic peptide (BNP; Nesiritide( )) in a concentration-dependent manner, which activated NPR-A s intracellular GC domain and triggered a corresponding cGMP surge. Cyclic GMP 298-302 natriuretic peptide receptor 1 Homo sapiens 36-66 25843350-4 2015 In cell lines expressing endogenous natriuretic peptide receptor A (NPR-A) (HeLa), GTA/PGTA-driven transgene expression was induced by B-type natriuretic peptide (BNP; Nesiritide( )) in a concentration-dependent manner, which activated NPR-A s intracellular GC domain and triggered a corresponding cGMP surge. Cyclic GMP 298-302 natriuretic peptide receptor 1 Homo sapiens 68-73 26589601-4 2015 We tested the association of 119 single nucleotide polymorphisms (SNPs) in 4 candidate genes (NPR1, NPR2, NPR3, and membrane metallo-endopeptidase (MME)) with the change in cGMP and BP. Cyclic GMP 173-177 natriuretic peptide receptor 1 Homo sapiens 94-98 26374856-8 2015 Thus, after ligand binding, NPRA is rapidly internalized and trafficked from the cell surface into endosomes, Res and lysosomes, with concurrent generation of intracellular cGMP. Cyclic GMP 173-177 natriuretic peptide receptor 1 Homo sapiens 28-32 26151885-3 2015 Cardiac hormones, atrial and brain natriuretic peptides (ANP and BNP) bind to guanylyl cyclase/natriuretic peptide receptor-A (GC-A/NPRA) and elicit the generation of intracellular second messenger cyclic guanosine 3",5"-monophosphate (cGMP), which lowers blood pressure and incidence of heart failure. Cyclic GMP 198-234 natriuretic peptide receptor 1 Homo sapiens 95-125 26151885-3 2015 Cardiac hormones, atrial and brain natriuretic peptides (ANP and BNP) bind to guanylyl cyclase/natriuretic peptide receptor-A (GC-A/NPRA) and elicit the generation of intracellular second messenger cyclic guanosine 3",5"-monophosphate (cGMP), which lowers blood pressure and incidence of heart failure. Cyclic GMP 236-240 natriuretic peptide receptor 1 Homo sapiens 95-125 25202235-5 2014 The activation of NPRB in response to CNP also produces the intracellular cGMP; however, at lower magnitude than that of NPRA, which is activated by ANP and BNP. Cyclic GMP 74-78 natriuretic peptide receptor 1 Homo sapiens 121-125 25202235-9 2014 This review focuses on the signaling mechanisms of ANP/NPRA and their biological effects involving an increased level of intracellular accumulation of cGMP and a decreased level of cAMP, Ca(2+), and IP3 in different cells and tissue systems. Cyclic GMP 151-155 natriuretic peptide receptor 1 Homo sapiens 55-59 21375691-1 2011 The cardiac hormones atrial natriuretic peptide and B-type natriuretic peptide (brain natriuretic peptide) activate guanylyl cyclase (GC)-A/natriuretic peptide receptor-A (NPRA) and produce the second messenger cGMP. Cyclic GMP 211-215 natriuretic peptide receptor 1 Homo sapiens 172-176 23526266-7 2013 The cGMP analog (8-bromo-cGMP) treatment significantly attenuated the agonist-induced collagen synthesis both in normal and NPR-A-suppressed adult cells. Cyclic GMP 4-8 natriuretic peptide receptor 1 Homo sapiens 124-129 23638320-7 2013 ANP-dependent stimulation of intracellular accumulation of cGMP and guanylyl cyclase activity of NPRA were significantly reduced in Npr1 miRNA-expressing cells by 90-95% as compared with control cells. Cyclic GMP 59-63 natriuretic peptide receptor 1 Homo sapiens 132-136 20178049-3 2010 CD-NP is able to bind to all three natriuretic peptide receptors (NPR-A, NPR-B and NPR-C) and, therefore, is unique in being able to increase cyclic guanosine monophosphate production downstream of both NPR-A and NPR-B. Cyclic GMP 142-172 natriuretic peptide receptor 1 Homo sapiens 203-208 20444705-0 2010 GREBP, a cGMP-response element-binding protein repressing the transcription of natriuretic peptide receptor 1 (NPR1/GCA). Cyclic GMP 9-13 natriuretic peptide receptor 1 Homo sapiens 79-109 20444705-0 2010 GREBP, a cGMP-response element-binding protein repressing the transcription of natriuretic peptide receptor 1 (NPR1/GCA). Cyclic GMP 9-13 natriuretic peptide receptor 1 Homo sapiens 111-115 20444705-2 2010 After ANP stimulation, NPR1/GCA down-regulates the transcriptional activity of its gene via a cGMP-dependent mechanism. Cyclic GMP 94-98 natriuretic peptide receptor 1 Homo sapiens 23-27 20444705-8 2010 By acting on cGMP-RE, GREBP inhibited the expression of a luciferase-coupled NPR1 promoter construct. Cyclic GMP 13-17 natriuretic peptide receptor 1 Homo sapiens 77-81 20214400-2 2010 NPRA activation by atrial natriuretic peptide (ANP) leads to cGMP production, which plays important roles in cardiovascular homeostasis. Cyclic GMP 61-65 natriuretic peptide receptor 1 Homo sapiens 0-4 20506274-10 2010 These studies suggest that both RGD containing ECM proteins and integrins may interact with BNP/NPR-A to modulate cGMP generation. Cyclic GMP 114-118 natriuretic peptide receptor 1 Homo sapiens 96-101 17965196-2 2008 The natural agonists atrial and brain natriuretic peptides (ANP, BNP) bind and activate NPRA, leading to cyclic GMP production, which is responsible for their role in cardiovascular homeostasis. Cyclic GMP 105-115 natriuretic peptide receptor 1 Homo sapiens 88-92 18651838-1 2009 ANP (atrial natriuretic peptide) exerts its biological effects by binding to GC (guanylate cyclase)-A/NPR (natriuretic peptide receptor)-A, which generates the second messenger cGMP. Cyclic GMP 177-181 natriuretic peptide receptor 1 Homo sapiens 107-138 18006579-2 2008 The biological effects of NPs have been mainly attributed to changes in intracellular cGMP following their binding to NPR-A and NPR-B. Cyclic GMP 86-90 natriuretic peptide receptor 1 Homo sapiens 118-123 17848634-1 2007 Natriuretic peptide receptors A (NPR-A) and B (NPR-B) mediate most effects of natriuretic peptides by synthesizing cGMP. Cyclic GMP 115-119 natriuretic peptide receptor 1 Homo sapiens 0-31 18703404-5 2008 NPR-A and NPR-B are guanylyl cyclase receptors that increase intracellular cGMP concentration and activate cGMP-dependent protein kinases. Cyclic GMP 75-79 natriuretic peptide receptor 1 Homo sapiens 0-5 17848634-1 2007 Natriuretic peptide receptors A (NPR-A) and B (NPR-B) mediate most effects of natriuretic peptides by synthesizing cGMP. Cyclic GMP 115-119 natriuretic peptide receptor 1 Homo sapiens 33-45 16986166-4 2006 The goal of the current investigation was to determine potential interactions between FN and NPR-A on BNP induction of cGMP in cultured human cardiac fibroblasts (CFs). Cyclic GMP 119-123 natriuretic peptide receptor 1 Homo sapiens 93-98 17440808-7 2007 Activation of NPR-A generates an increase in cyclic guanosine monophosphate, which mediates natriuresis, inhibition of renin and aldosterone, as well as vasorelaxant, anti-fibrotic, anti-hypertrophic, and lusitropic effects. Cyclic GMP 45-75 natriuretic peptide receptor 1 Homo sapiens 14-19 16986166-8 2006 This production was also enhanced by the NPR-A specific RGD peptide, which further augmented FN associated cGMP production. Cyclic GMP 107-111 natriuretic peptide receptor 1 Homo sapiens 41-46 16986166-11 2006 We conclude that NPR-A interacts with components of the ECM such as FN to enhance BNP activation of cGMP and that a small NPR-A specific RGD peptide augments this action of BNP with possible therapeutic implications. Cyclic GMP 100-104 natriuretic peptide receptor 1 Homo sapiens 17-22 16291870-4 2006 Two, NPR-A/GC-A/NPR1 and NPR-B/GC-B/NPR2, are transmembrane guanylyl cyclases, enzymes that catalyze the synthesis of cGMP. Cyclic GMP 118-122 natriuretic peptide receptor 1 Homo sapiens 5-10 16291870-4 2006 Two, NPR-A/GC-A/NPR1 and NPR-B/GC-B/NPR2, are transmembrane guanylyl cyclases, enzymes that catalyze the synthesis of cGMP. Cyclic GMP 118-122 natriuretic peptide receptor 1 Homo sapiens 16-20 15758553-6 2005 NPRA and NPRB are guanylyl cyclase receptors, and their activation increases cGMP levels. Cyclic GMP 77-81 natriuretic peptide receptor 1 Homo sapiens 0-4 15096467-1 2004 Previous studies have shown that atrial natriuretic peptide (ANP) can inhibit transcription of its receptor, guanylyl cyclase A, by a mechanism dependent on cGMP and have suggested the presence of a putative cGMP-response element (cGMP-RE) in the Npr1 gene promoter. Cyclic GMP 208-212 natriuretic peptide receptor 1 Homo sapiens 247-251 15459247-1 2005 Natriuretic peptide receptor A (NPR-A/GC-A) and B (NPR-B/GC-B) are members of the transmembrane guanylyl cyclase family that mediate the effects of natriuretic peptides via the second messenger, cGMP. Cyclic GMP 195-199 natriuretic peptide receptor 1 Homo sapiens 0-30 15459247-1 2005 Natriuretic peptide receptor A (NPR-A/GC-A) and B (NPR-B/GC-B) are members of the transmembrane guanylyl cyclase family that mediate the effects of natriuretic peptides via the second messenger, cGMP. Cyclic GMP 195-199 natriuretic peptide receptor 1 Homo sapiens 32-37 15096467-1 2004 Previous studies have shown that atrial natriuretic peptide (ANP) can inhibit transcription of its receptor, guanylyl cyclase A, by a mechanism dependent on cGMP and have suggested the presence of a putative cGMP-response element (cGMP-RE) in the Npr1 gene promoter. Cyclic GMP 208-212 natriuretic peptide receptor 1 Homo sapiens 247-251 15096467-7 2004 The cGMP regulatory region was narrowed by gel shift assays and footprinting to position -1372 to -1354 from the transcription start site of Npr1 and indicated its interaction with transcriptional factor(s). Cyclic GMP 4-8 natriuretic peptide receptor 1 Homo sapiens 141-145 11927396-10 2002 These results suggest that the actions of NPR-A and NPR-B, functional receptors in the human thyroid cell, may in part be mediated by cGMP-induced alterations in the cytoskeleton. Cyclic GMP 134-138 natriuretic peptide receptor 1 Homo sapiens 42-47 14757224-8 2004 The data obtained indicate that this effect is mediated by the activation of the NPR-A/guanylate cyclase/cGMP pathway. Cyclic GMP 105-109 natriuretic peptide receptor 1 Homo sapiens 81-86 12855709-2 2003 Natriuretic peptide binding to type I receptors (NPRA and NPRB) activates their intrinsic guanylyl cyclase activity, resulting in a rapid increase in cytosolic cGMP that subsequently activates PKG. Cyclic GMP 160-164 natriuretic peptide receptor 1 Homo sapiens 49-53 12855709-10 2003 As such, the NPRA-PKG association may represent a novel mechanism for compartmentation of cGMP-mediated signaling and regulation of receptor sensitivity. Cyclic GMP 90-94 natriuretic peptide receptor 1 Homo sapiens 13-17 11551207-2 2001 Upon stimulation, NPR-A receptors are activated to produce cyclic guanosine monophosphate (cGMP) and are subsequently desensitized through dephosphorylation of residues at their KHD. Cyclic GMP 59-89 natriuretic peptide receptor 1 Homo sapiens 18-23 11551207-2 2001 Upon stimulation, NPR-A receptors are activated to produce cyclic guanosine monophosphate (cGMP) and are subsequently desensitized through dephosphorylation of residues at their KHD. Cyclic GMP 91-95 natriuretic peptide receptor 1 Homo sapiens 18-23 10980893-4 2000 ANP and BNP bind to the natriuretic peptide-A receptor (NPR-A), which, via 3",5"-cyclic guanosine monophosphate (cGMP), mediates natriuresis, vasodilatation, renin inhibition, antimitogenesis, and lusitropic properties. Cyclic GMP 113-117 natriuretic peptide receptor 1 Homo sapiens 56-61 11476737-7 2001 Guanylate cyclase forms three types of ANP receptors, although NPR-A and B (GC-A and B) are biologically active and related to the synthesis of cGMP. Cyclic GMP 144-148 natriuretic peptide receptor 1 Homo sapiens 63-74 11212968-5 2001 However, at confluence mRNA transcripts for both the NPR-A and -B were expressed, accompanied by a significant cyclic guanosine monophosphate (cGMP) response to ANP and CNP, indicating the development of functionally active receptors. Cyclic GMP 111-141 natriuretic peptide receptor 1 Homo sapiens 53-65 11212968-5 2001 However, at confluence mRNA transcripts for both the NPR-A and -B were expressed, accompanied by a significant cyclic guanosine monophosphate (cGMP) response to ANP and CNP, indicating the development of functionally active receptors. Cyclic GMP 143-147 natriuretic peptide receptor 1 Homo sapiens 53-65 10915802-1 2000 The binding of atrial natriuretic peptide and C-type natriuretic peptide (CNP) to the guanylyl cyclase-linked natriuretic peptide receptors A and B (NPR-A and -B), respectively, stimulates increases in intracellular cGMP concentrations. Cyclic GMP 216-220 natriuretic peptide receptor 1 Homo sapiens 149-161 11306239-4 2001 The R1 subclass of NP receptors (NPR-A and NPR-B) contains a C-terminal guanylyl cyclase domain and is responsible for most of the NPs downstream actions through their ability to generate cGMP. Cyclic GMP 188-192 natriuretic peptide receptor 1 Homo sapiens 33-38 9689013-8 1998 8-Bromo-cGMP was also effective in inhibiting NPR-A mRNA levels and NPR-A promoter activity, suggesting that the second messenger (i.e., cGMP) rather than ANP, itself, is responsible for downregulation of NPR-A gene expression. Cyclic GMP 8-12 natriuretic peptide receptor 1 Homo sapiens 46-51 10222228-4 1999 NPR-A and NPR-B receptors elicited a cGMP response to ANP, BNP, and CNP, in a rank order of potency (CNP >> ANP >/= BNP), indicative that the NPR-B receptor is predominant in NPE cells. Cyclic GMP 37-41 natriuretic peptide receptor 1 Homo sapiens 0-5 10222228-5 1999 A71915, an inhibitor of NPR-A activity, attenuated (65-75%) cGMP response to ANP and BNP, but not to CNP. Cyclic GMP 60-64 natriuretic peptide receptor 1 Homo sapiens 24-29 10677348-10 2000 On the other hand, ANP-A/B-receptor-mediated increases in cGMP levels were not inhibited by antisense-oligonucleotide treatment. Cyclic GMP 58-62 natriuretic peptide receptor 1 Homo sapiens 19-24 10519161-3 1999 ANP and BNP bind to the natriuretic peptide-A receptor (NPR-A), which, via 3",5"-cyclic guanosine monophosphate (cGMP), mediates natriuresis, vasodilation, renin inhibition, antimitogenesis, and lusitropic properties. Cyclic GMP 113-117 natriuretic peptide receptor 1 Homo sapiens 56-61 9689013-8 1998 8-Bromo-cGMP was also effective in inhibiting NPR-A mRNA levels and NPR-A promoter activity, suggesting that the second messenger (i.e., cGMP) rather than ANP, itself, is responsible for downregulation of NPR-A gene expression. Cyclic GMP 8-12 natriuretic peptide receptor 1 Homo sapiens 68-73 9689013-8 1998 8-Bromo-cGMP was also effective in inhibiting NPR-A mRNA levels and NPR-A promoter activity, suggesting that the second messenger (i.e., cGMP) rather than ANP, itself, is responsible for downregulation of NPR-A gene expression. Cyclic GMP 8-12 natriuretic peptide receptor 1 Homo sapiens 68-73 7915521-4 1994 The in vitro cGMP generation assay revealed that the expression of ANP-A receptor was more prominent than that of ANP-B receptor in these tissues. Cyclic GMP 13-17 natriuretic peptide receptor 1 Homo sapiens 67-72 9486150-3 1998 Typically, ANP exerts some of its actions via activation of the ANP receptor (ANPR-A), a particulate guanylyl cyclase-linked receptor, and subsequent formation of guanosine 3",5"-cyclic monophosphate (cGMP). Cyclic GMP 163-199 natriuretic peptide receptor 1 Homo sapiens 78-84 9486150-3 1998 Typically, ANP exerts some of its actions via activation of the ANP receptor (ANPR-A), a particulate guanylyl cyclase-linked receptor, and subsequent formation of guanosine 3",5"-cyclic monophosphate (cGMP). Cyclic GMP 201-205 natriuretic peptide receptor 1 Homo sapiens 78-84 9322941-8 1997 The effect of ANP was mediated via the guanylate cyclase coupled NPR-A as shown by experiments employing stable cGMP analogs, the NPR-A antagonist HS-142-1, LY-83583, a cGMP inhibitor as well as C-ANF, a specific ligand of the NPR-C. Cyclic GMP 112-116 natriuretic peptide receptor 1 Homo sapiens 65-70 9322941-8 1997 The effect of ANP was mediated via the guanylate cyclase coupled NPR-A as shown by experiments employing stable cGMP analogs, the NPR-A antagonist HS-142-1, LY-83583, a cGMP inhibitor as well as C-ANF, a specific ligand of the NPR-C. Cyclic GMP 169-173 natriuretic peptide receptor 1 Homo sapiens 65-70 9322941-8 1997 The effect of ANP was mediated via the guanylate cyclase coupled NPR-A as shown by experiments employing stable cGMP analogs, the NPR-A antagonist HS-142-1, LY-83583, a cGMP inhibitor as well as C-ANF, a specific ligand of the NPR-C. Cyclic GMP 169-173 natriuretic peptide receptor 1 Homo sapiens 130-135 9512977-7 1998 After release from distal tubular kidney cells into the tubular lumen, URO binds to luminal receptors (NPR-A) in the collecting duct resulting in a cGMP-dependent signal transduction. Cyclic GMP 148-152 natriuretic peptide receptor 1 Homo sapiens 103-108 8995744-2 1997 ANP and C-type natriuretic peptide (CNP) induced a concentration-dependent increase in cGMP suggesting the presence of type-A (NPR-A) and type-B (NPR-B) receptors, respectively. Cyclic GMP 87-91 natriuretic peptide receptor 1 Homo sapiens 127-144 1358197-1 1992 The human natriuretic peptide receptor-A (NPR-A) guanylyl cyclase is specifically activated to synthesize cGMP by binding of atrial natriuretic peptide (ANP) to the receptor"s extracellular domain. Cyclic GMP 106-110 natriuretic peptide receptor 1 Homo sapiens 10-40 1358197-1 1992 The human natriuretic peptide receptor-A (NPR-A) guanylyl cyclase is specifically activated to synthesize cGMP by binding of atrial natriuretic peptide (ANP) to the receptor"s extracellular domain. Cyclic GMP 106-110 natriuretic peptide receptor 1 Homo sapiens 42-47 1358197-7 1992 When whole cell stimulation of cGMP production by ANP was tested on the low level of endogenous 293 cell NPR-A, maximal stimulation was observed regardless of truncated NPR-A overexpression. Cyclic GMP 31-35 natriuretic peptide receptor 1 Homo sapiens 105-110 1327579-6 1992 Of the three known NPRs, two, NPR-A and NPR-B, are capable of synthesizing their own second messenger, cGMP. Cyclic GMP 103-107 natriuretic peptide receptor 1 Homo sapiens 30-35 1319147-2 1992 This analog, which retains many of the spatial relationships of the native molecule, binds to both ANP-A and ANP-C receptor subtypes, and triggers the production of cyclic-GMP by ANP-A. Cyclic GMP 165-175 natriuretic peptide receptor 1 Homo sapiens 179-184 1309330-2 1992 Using these receptor preparations, we examined the binding affinities of ANP, BNP, and CNP for the C-receptor and their potencies for cGMP production via the ANP-A receptor (GC-A) and the ANP-B receptor (GC-B). Cyclic GMP 134-138 natriuretic peptide receptor 1 Homo sapiens 174-178 1309330-6 1992 The rank order of potency for cGMP production via the ANP-A receptor (GC-A) was ANP greater than or equal to BNP much greater than CNP, but that via the ANP-B receptor (GC-B) was CNP greater than ANP greater than or equal to BNP. Cyclic GMP 30-34 natriuretic peptide receptor 1 Homo sapiens 70-74 1660465-3 1991 Two of these receptors, designated NPR-A and NPR-B, are membrane guanylyl cyclases that synthesize cGMP in response to hormone stimulation. Cyclic GMP 99-103 natriuretic peptide receptor 1 Homo sapiens 35-40 34268307-6 2021 Our recently published investigation revealed that ANP could promote the neurite outgrowth of SGNs by activating NPR-A/cGMP/PKG cascade in a dose-dependent manner. Cyclic GMP 119-123 natriuretic peptide receptor 1 Homo sapiens 113-118 34268307-8 2021 Our data indicated that ANP could support and attract neurite outgrowth of SGNs and possess a high capacity to improve neuronal survival of SGNs against glutamate-induced excitotoxicity by triggering the NPR-A/cGMP/PKG pathway. Cyclic GMP 210-214 natriuretic peptide receptor 1 Homo sapiens 204-209 34268307-9 2021 The neuroregenerative and neuroprotective effects of ANP/NPRA/cGMP/PKG-dependent signaling on SGNs would represent an attractive therapeutic candidate for hearing impairment. Cyclic GMP 62-66 natriuretic peptide receptor 1 Homo sapiens 57-61 35233476-2 2022 NPR-C acts as a clearance receptor of natriuretic peptides, including C-type natriuretic peptide (CNP), that stimulate the cGMP-forming guanylyl cyclase-coupled receptors NPR-A and NPR-B. Cyclic GMP 123-127 natriuretic peptide receptor 1 Homo sapiens 171-176